GT Biopharma (GTBP) had the highest return in 1998 by a US stock in the Biotechnology Industry, returning 513.3%.
| ASSET | YEAR | % RETURN |
|---|---|---|
GT Biopharma (GTBP) | 1998 | 513.27% |
Amgen (AMGN) | 1998 | 93.41% |
CASI Pharmaceuticals (CASI) | 1998 | 84.62% |
Arrowhead Pharmaceuticals (ARWR) | 1998 | 60% |
Lifecore Biomedical (LFCR) | 1998 | 50% |
Biogen (BIIB) | 1998 | 36.73% |
Geron (GERN) | 1998 | 27.94% |
Lisata Therapeutics (LSTA) | 1998 | 27.27% |
Alkermes (ALKS) | 1998 | 11.64% |
Gilead Sciences (GILD) | 1998 | 7.36% |
Ionis Pharmaceuticals (IONS) | 1998 | 2.98% |
Opko Health (OPK) | 1998 | 0.92% |
CervoMed (CRVO) | 1998 | 0% |
BioRestorative Therapies (BRTX) | 1998 | 0% |
Protagenic Therapeutics (PTIX) | 1998 | 0% |
Oruka Therapeutics (ORKA) | 1998 | 0% |
Tenax Therapeutics (TENX) | 1998 | 0% |
BioCryst Pharmaceuticals (BCRX) | 1998 | 0% |
Compass Therapeutics (CMPX) | 1998 | 0% |
Marker Therapeutics (MRKR) | 1998 | 0% |
Enveric Biosciences (ENVB) | 1998 | -0.86% |
Lineage Cell Therapeutics (LCTX) | 1998 | -3.14% |
Insmed (INSM) | 1998 | -6.9% |
Vertex Pharmaceuticals (VRTX) | 1998 | -8.81% |
Vera Therapeutics (VERA) | 1998 | -9.8% |
